Company news
Adial Pharmaceuticals, Inc news in 2022
Adial Pharmaceuticals, Inc's news releases, calls and decks from 2022, newest first.
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 13, 2022
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain
September 25, 2022
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis
September 5, 2022
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer
August 21, 2022
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 15, 2022
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
July 19, 2022
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
July 17, 2022
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
June 26, 2022
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence
June 13, 2022
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH
May 18, 2022
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 15, 2022
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
May 3, 2022
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
February 23, 2022
Adial Pharmaceuticals Announces Closing of $10 Million Financing
February 15, 2022
Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering
February 10, 2022
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma
February 8, 2022
Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04
January 23, 2022
Decks in 2022
- Investor Presentation (August 2022)
Investor deck · 28 slides · August 2022
- Investor Presentation (May 2022)
Investor deck · 28 slides · May 2022
- Investor Presentation (January 2022)
Investor deck · 28 slides · January 2022